Annual EBITDA:
-$447.31M-$244.61M(-120.67%)Summary
- As of today, CRSP annual EBITDA is -$447.31 million, with the most recent change of -$244.61 million (-120.67%) on December 31, 2024.
- During the last 3 years, CRSP annual EBITDA has fallen by -$838.79 million (-214.26%).
- CRSP annual EBITDA is now -214.26% below its all-time high of $391.48 million, reached on December 31, 2021.
Performance
CRSP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$128.47M+$15.22M(+10.59%)Summary
- As of today, CRSP quarterly EBITDA is -$128.47 million, with the most recent change of +$15.22 million (+10.59%) on June 30, 2025.
- Over the past year, CRSP quarterly EBITDA has increased by +$17.94 million (+12.26%).
- CRSP quarterly EBITDA is now -116.77% below its all-time high of $766.27 million, reached on June 30, 2021.
Performance
CRSP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$437.24M+$17.94M(+3.94%)Summary
- As of today, CRSP TTM EBITDA is -$437.24 million, with the most recent change of +$17.94 million (+3.94%) on June 30, 2025.
- Over the past year, CRSP TTM EBITDA has dropped by -$125.48 million (-40.25%).
- CRSP TTM EBITDA is now -195.22% below its all-time high of $459.18 million, reached on June 30, 2021.
Performance
CRSP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRSP EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -120.7% | +12.3% | -40.3% |
| 3Y3 Years | -214.3% | +27.0% | +28.2% |
| 5Y5 Years | -969.1% | -63.7% | -92.1% |
CRSP EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -214.3% | +31.1% | -272.5% | +27.6% | -143.9% | +34.0% |
| 5Y | 5-Year | -214.3% | +31.1% | -116.8% | +27.6% | -195.2% | +34.0% |
| All-Time | All-Time | -214.3% | +31.1% | -116.8% | +27.6% | -195.2% | +34.0% |
CRSP EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$128.47M(+10.6%) | -$437.24M(+3.9%) |
| Mar 2025 | - | -$143.69M(-140.5%) | -$455.18M(-1.8%) |
| Dec 2024 | -$447.31M(-120.7%) | -$59.75M(+43.3%) | -$447.25M(-42.9%) |
| Sep 2024 | - | -$105.33M(+28.1%) | -$313.02M(-0.4%) |
| Jun 2024 | - | -$146.41M(-7.9%) | -$311.75M(-22.0%) |
| Mar 2024 | - | -$135.75M(-282.3%) | -$255.60M(-42.6%) |
| Dec 2023 | -$202.70M(+68.8%) | $74.48M(+171.6%) | -$179.28M(+52.8%) |
| Sep 2023 | - | -$104.06M(-15.3%) | -$379.46M(+16.2%) |
| Jun 2023 | - | -$90.26M(-51.9%) | -$452.76M(+15.9%) |
| Mar 2023 | - | -$59.44M(+52.7%) | -$538.49M(+17.0%) |
| Dec 2022 | -$648.99M(-265.8%) | -$125.69M(+29.1%) | -$648.99M(+2.1%) |
| Sep 2022 | - | -$177.37M(-0.8%) | -$662.73M(-8.8%) |
| Jun 2022 | - | -$175.99M(-3.6%) | -$608.89M(-282.6%) |
| Mar 2022 | - | -$169.93M(-21.9%) | $333.38M(-14.8%) |
| Dec 2021 | $391.48M(+213.4%) | -$139.44M(-12.9%) | $391.48M(-8.0%) |
| Sep 2021 | - | -$123.53M(-116.1%) | $425.72M(-7.3%) |
| Jun 2021 | - | $766.27M(+785.2%) | $459.18M(+219.1%) |
| Mar 2021 | - | -$111.83M(-6.3%) | -$385.58M(-11.7%) |
| Dec 2020 | -$345.25M | -$105.19M(-16.8%) | -$345.24M(-51.7%) |
| Sep 2020 | - | -$90.06M(-14.7%) | -$227.63M(-8009.4%) |
| Jun 2020 | - | -$78.50M(-9.8%) | $2.88M(-89.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$71.49M(-675.8%) | $27.59M(-46.6%) |
| Dec 2019 | $51.47M(+133.1%) | $12.41M(-91.2%) | $51.65M(+1123.8%) |
| Sep 2019 | - | $140.45M(+361.1%) | -$5.04M(+97.4%) |
| Jun 2019 | - | -$53.78M(-13.4%) | -$194.04M(-9.8%) |
| Mar 2019 | - | -$47.42M(-7.1%) | -$176.68M(-13.7%) |
| Dec 2018 | -$155.42M(-152.2%) | -$44.28M(+8.8%) | -$155.42M(-42.2%) |
| Sep 2018 | - | -$48.55M(-33.3%) | -$109.29M(-30.9%) |
| Jun 2018 | - | -$36.42M(-39.2%) | -$83.51M(-23.4%) |
| Mar 2018 | - | -$26.17M(-1511.6%) | -$67.69M(-10.0%) |
| Dec 2017 | -$61.62M(-348.4%) | $1.85M(+108.1%) | -$61.54M(+30.2%) |
| Sep 2017 | - | -$22.77M(-10.5%) | -$88.22M(-10.5%) |
| Jun 2017 | - | -$20.60M(-2.9%) | -$79.82M(-5.6%) |
| Mar 2017 | - | -$20.02M(+19.3%) | -$75.61M(-12.6%) |
| Dec 2016 | -$13.74M(+46.3%) | -$24.82M(-72.7%) | -$67.13M(-58.7%) |
| Sep 2016 | - | -$14.37M(+12.3%) | -$42.31M(-51.5%) |
| Jun 2016 | - | -$16.39M(-41.9%) | -$27.93M(-84.3%) |
| Mar 2016 | - | -$11.55M(-219.7%) | -$15.16M(-106.7%) |
| Dec 2015 | -$25.59M(-274.9%) | - | - |
| Jun 2015 | - | -$3.61M(+3.0%) | -$7.33M(-97.0%) |
| Mar 2015 | - | -$3.72M | -$3.72M |
| Dec 2014 | -$6.83M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual EBITDA?
- What is the all-time high annual EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
- What is CRISPR Therapeutics AG quarterly EBITDA?
- What is the all-time high quarterly EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
- What is CRISPR Therapeutics AG TTM EBITDA?
- What is the all-time high TTM EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
What is CRISPR Therapeutics AG annual EBITDA?
The current annual EBITDA of CRSP is -$447.31M
What is the all-time high annual EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual EBITDA is $391.48M
What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
Over the past year, CRSP annual EBITDA has changed by -$244.61M (-120.67%)
What is CRISPR Therapeutics AG quarterly EBITDA?
The current quarterly EBITDA of CRSP is -$128.47M
What is the all-time high quarterly EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly EBITDA is $766.27M
What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
Over the past year, CRSP quarterly EBITDA has changed by +$17.94M (+12.26%)
What is CRISPR Therapeutics AG TTM EBITDA?
The current TTM EBITDA of CRSP is -$437.24M
What is the all-time high TTM EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM EBITDA is $459.18M
What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
Over the past year, CRSP TTM EBITDA has changed by -$125.48M (-40.25%)